Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-022820
Filing Date
2025-08-08
Accepted
2025-08-08 17:17:38
Documents
19
Period of Report
2025-08-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm   iXBRL DEF 14A 423309
2 GRAPHIC proxy_001.jpg GRAPHIC 1685315
3 GRAPHIC proxy_002.jpg GRAPHIC 1520559
  Complete submission text file 0001641172-25-022820.txt   7488584

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ltrn-20241231.xsd EX-101.SCH 3431
5 XBRL DEFINITION FILE ltrn-20241231_def.xml EX-101.DEF 5353
6 XBRL LABEL FILE ltrn-20241231_lab.xml EX-101.LAB 52602
7 XBRL PRESENTATION FILE ltrn-20241231_pre.xml EX-101.PRE 38698
22 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 7552
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39318 | Film No.: 251199451
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)